Does the media refer more to CYRX or LAB?

In the previous week, CryoPort and CryoPort both had 2 articles in the media. Standard BioTools' average media sentiment score of 1.86 beat CryoPort's score of 1.84 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to MLAB or LAB?

In the previous week, Mesa Laboratories had 2 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Mesa Laboratories and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat Mesa Laboratories' score of 1.41 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is LAB or OABI more profitable?

Standard BioTools has a net margin of 100.36% compared to OmniAb's net margin of -115.12%. Standard BioTools' return on equity of -7.57% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets Standard BioTools 100.36% -7.57% -6.14% OmniAb -115.12% -16.59% -14.82%

Does the media prefer LAB or OABI?

In the previous week, OmniAb had 6 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for OmniAb and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat OmniAb's score of 0.76 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, EVO or LAB?

Standard BioTools has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $717.28M 0.95 -$117.12M N/A N/A Standard BioTools $85.33M 2.95 -$74.90M $0.22 2.92

Is EVO or LAB more profitable?

Standard BioTools has a net margin of 100.36% compared to Evotec's net margin of -26.20%. Standard BioTools' return on equity of -7.57% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Standard BioTools 100.36% -7.57% -6.14%

Does the media favor EVO or LAB?

In the previous week, Evotec had 3 more articles in the media than Standard BioTools. MarketBeat recorded 5 mentions for Evotec and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat Evotec's score of -0.07 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CTKB or LAB?

In the previous week, Cytek Biosciences had 2 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Cytek Biosciences and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat Cytek Biosciences' score of 1.27 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Standard BioTools (LAB) Competitors

$0.64 -0.01 (-1.70%)

As of 08/28/2026 04:00 PM Eastern

Compare

LAB vs. CYRX, MLAB, OABI, EVO, and CTKB

Should you buy Standard BioTools stock or one of its competitors? Standard BioTools's main competitors and comparable companies include CryoPort (CYRX), Mesa Laboratories (MLAB), OmniAb (OABI), Evotec (EVO), and Cytek Biosciences (CTKB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Standard BioTools compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Standard BioTools has a net margin of 100.36% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Standard BioTools	100.36%	-7.57%	-6.14%

CryoPort currently has a consensus price target of $18.00, suggesting a potential upside of 11.87%. Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 110.31%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, CryoPort and CryoPort both had 2 articles in the media. Standard BioTools' average media sentiment score of 1.86 beat CryoPort's score of 1.84 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Comparatively, 26.8% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CryoPort has higher revenue and earnings than Standard BioTools. CryoPort is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.63	$78.30M	-$0.90	N/A
Standard BioTools	$85.33M	2.95	-$74.90M	$0.22	2.92

Summary

CryoPort beats Standard BioTools on 9 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Mesa Laboratories had 2 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Mesa Laboratories and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat Mesa Laboratories' score of 1.41 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Mesa Laboratories has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Mesa Laboratories has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.90	$6.71M	$0.84	153.68
Standard BioTools	$85.33M	2.95	-$74.90M	$0.22	2.92

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by insiders. Comparatively, 26.8% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Standard BioTools has a net margin of 100.36% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Standard BioTools	100.36%	-7.57%	-6.14%

Mesa Laboratories presently has a consensus target price of $110.00, suggesting a potential downside of 14.79%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 110.31%. Given Standard BioTools' higher probable upside, analysts plainly believe Standard BioTools is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Mesa Laboratories beats Standard BioTools on 9 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to OmniAb?

Standard BioTools (NASDAQ:LAB) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Standard BioTools has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

OmniAb has lower revenue, but higher earnings than Standard BioTools. OmniAb is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	2.95	-$74.90M	$0.22	2.92
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Standard BioTools has a net margin of 100.36% compared to OmniAb's net margin of -115.12%. Standard BioTools' return on equity of -7.57% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
OmniAb	-115.12%	-16.59%	-14.82%

In the previous week, OmniAb had 6 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for OmniAb and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat OmniAb's score of 0.76 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Standard BioTools presently has a consensus price target of $1.35, indicating a potential upside of 110.31%. OmniAb has a consensus price target of $11.00, indicating a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Standard BioTools beats OmniAb on 9 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Evotec?

Evotec (NASDAQ:EVO) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Evotec has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

5.8% of Evotec shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Standard BioTools has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$717.28M	0.95	-$117.12M	N/A	N/A
Standard BioTools	$85.33M	2.95	-$74.90M	$0.22	2.92

Standard BioTools has a net margin of 100.36% compared to Evotec's net margin of -26.20%. Standard BioTools' return on equity of -7.57% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Standard BioTools	100.36%	-7.57%	-6.14%

Evotec presently has a consensus price target of $3.00, suggesting a potential upside of 57.07%. Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 110.31%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Evotec had 3 more articles in the media than Standard BioTools. MarketBeat recorded 5 mentions for Evotec and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat Evotec's score of -0.07 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Standard BioTools beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Standard BioTools compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cytek Biosciences has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Standard BioTools has a net margin of 100.36% compared to Cytek Biosciences' net margin of -38.98%. Standard BioTools' return on equity of -7.57% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Standard BioTools	100.36%	-7.57%	-6.14%

Cytek Biosciences presently has a consensus price target of $5.56, indicating a potential upside of 18.86%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 110.31%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Cytek Biosciences had 2 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Cytek Biosciences and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.86 beat Cytek Biosciences' score of 1.27 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.02	-$66.54M	-$0.62	N/A
Standard BioTools	$85.33M	2.95	-$74.90M	$0.22	2.92

Summary

Standard BioTools beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$252M	$10.11B	$7.20B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	2.92	62.76	273.16	25.45
Price / Sales	2.95	111.63	605.01	76.63
Price / Cash	N/A	26.70	76.74	53.00
Price / Book	0.47	37.29	12.98	6.14
Net Income	-$74.90M	$56.67B	$3.48B	$348.86M
7 Day Performance	-4.05%	-1.52%	0.13%	-0.80%
1 Month Performance	-28.46%	7.21%	7.08%	4.13%
1 Year Performance	-49.06%	24.31%	24.67%	15.17%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	3.8891 of 5 stars	$0.64 -1.7%	$1.35 +110.3%	-49.1%	$252M	$85.33M	2.92	620	Positive News
CYRX CryoPort	2.1858 of 5 stars	$16.64 +1.8%	$18.00 +8.2%	+81.6%	$840.79M	$176.18M	N/A	1,186	Positive News
MLAB Mesa Laboratories	1.5012 of 5 stars	$124.04 -0.2%	$110.00 -11.3%	+90.5%	$694.87M	$249.13M	147.72	680	Positive News
OABI OmniAb	2.4997 of 5 stars	$4.70 -0.1%	$11.00 +133.8%	+179.4%	$675.41M	$38.46M	N/A	7
EVO Evotec	2.6514 of 5 stars	$1.89 -0.3%	$3.00 +59.2%	-45.4%	$670.72M	$891.97M	N/A	4,553	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. CYRX, MLAB, OABI, EVO, and CTKB

How does Standard BioTools compare to CryoPort?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Summary

How does Standard BioTools compare to OmniAb?

Summary

How does Standard BioTools compare to Evotec?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. CYRX, MLAB, OABI, EVO, and CTKB

How does Standard BioTools compare to CryoPort?

Is CYRX or LAB more profitable?

Do analysts prefer CYRX or LAB?

Does the media refer more to CYRX or LAB?

Which has more risk and volatility, CYRX or LAB?

Do institutionals and insiders hold more shares of CYRX or LAB?

Which has higher valuation and earnings, CYRX or LAB?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Does the media refer more to MLAB or LAB?

Which has more risk & volatility, MLAB or LAB?

Which has better earnings & valuation, MLAB or LAB?

Do insiders and institutionals hold more shares of MLAB or LAB?

Is MLAB or LAB more profitable?

Do analysts recommend MLAB or LAB?

Summary

How does Standard BioTools compare to OmniAb?

Which has more volatility and risk, LAB or OABI?

Which has higher valuation & earnings, LAB or OABI?

Is LAB or OABI more profitable?

Does the media prefer LAB or OABI?

Do institutionals & insiders have more ownership in LAB or OABI?

Do analysts rate LAB or OABI?

Summary

How does Standard BioTools compare to Evotec?

Which has more volatility and risk, EVO or LAB?

Do insiders and institutionals hold more shares of EVO or LAB?

Which has better valuation & earnings, EVO or LAB?

Is EVO or LAB more profitable?

Do analysts prefer EVO or LAB?

Does the media favor EVO or LAB?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Do insiders & institutionals have more ownership in CTKB or LAB?

Which has more volatility & risk, CTKB or LAB?

Is CTKB or LAB more profitable?

Do analysts prefer CTKB or LAB?

Does the media prefer CTKB or LAB?

Which has stronger earnings and valuation, CTKB or LAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools